Pipeline: New therapies to come for debilitating eye diseases

Article

New drug from Gensight Biologics hits pipeline

GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.

Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.

Related: Myopia control data and whats to come with Dr. Noel Brennan

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!
Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
Dr Ashley Tucker Wallace discusses the intersection of pediatric dry eye and myopia control
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Related Content
Intravitreal implant shows potential for treating the root causes of glaucoma and diabetic retinopathy. - Image credit: ©Yakobchuk Olena—stock.adobe.com

Intravitreal implant shows potential for treating the root causes of glaucoma and diabetic retinopathy

Lynda Charters
July 1st 2025
Article
Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

June 30th 2025
Podcast
Prevent Blindness declares July to be Dry Eye Month, provides patient resources - Image credit: ©NanSan—stock.adobe.com

Prevent Blindness declares July to be Dry Eye Month, provides patient resources

Emily Kaiser Maharjan, Assistant Managing Editor
June 30th 2025
Article
Navigating the Glaucoma Therapeutic and Surgical Landscape from Conventional to Cutting Edge

Navigating the Glaucoma Therapeutic and Surgical Landscape from Conventional to Cutting Edge

June 30th 2025
Podcast
Child undergoing eye exam Image credit: AdobeStock/AlexisS/peopleimages.com

CooperVision’s Generation Sight initiative expands its reach for myopia management treatment

Jordana Joy, Associate Editor
June 25th 2025
Article
Glaucoma Foundation receives $2.5 million gift from the Herbert Simon Family Foundation - Image credit: ©Nata Bene—stock.adobe.com

Glaucoma Foundation receives $2.5 million gift from the Herbert Simon Family Foundation

Lynda Charters
June 23rd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.